Identification of Antibiotics That Diminish Disease in a Murine Model of Enterohemorrhagic Escherichia Coli Infection

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2020 Feb 5

PMID 32015030

Citations 12

Authors

Sabrina Muhlen

Isabell Ramming

Marina C Pils

Martin Koeppel

Jana Glaser

John Leong

Antje Flieger

Barbel Stecher

Petra Dersch

Affiliations

Soon will be listed here.

Abstract

Infections with enterohemorrhagic (EHEC) cause disease ranging from mild diarrhea to hemolytic-uremic syndrome (HUS) and are the most common cause of renal failure in children in high-income countries. The severity of the disease derives from the release of Shiga toxins (Stx). The use of antibiotics to treat EHEC infections is generally avoided, as it can result in increased expression. Here, we systematically tested different classes of antibiotics and found that their influence on expression and release varies significantly. We assessed a selection of these antibiotics using the ϕ mouse model and show that -inducing antibiotics resulted in weight loss and kidney damage despite clearance of the infection. However, several non-Stx-inducing antibiotics cleared bacterial infection without causing Stx-mediated pathology. Our results suggest that these antibiotics might be useful in the treatment of EHEC-infected human patients and decrease the risk of HUS development.

Citing Articles

Rapid Enzymatic Detection of Shiga-Toxin-Producing Using Fluorescence-Labeled Oligonucleotide Substrates.

Ramming I, Lang C, Hauf S, Kruger M, Worbs S, Peukert C ACS Infect Dis. 2024; 10(12):4103-4114.

PMID: 39576816 PMC: 11650650. DOI: 10.1021/acsinfecdis.4c00221.

Infection and antibiotic-associated changes in the fecal microbiota of ϕ-infected C57BL/6 mice.

Muhlen S, Heroven A, Elxnat B, Kahl S, Pieper D, Dersch P Antimicrob Agents Chemother. 2024; 68(5):e0005724.

PMID: 38526080 PMC: 11064522. DOI: 10.1128/aac.00057-24.

Pathogenic in the Food Chain across the Arab Countries: A Descriptive Review.

Mohamed M, Habib I Foods. 2023; 12(20).

PMID: 37893619 PMC: 10606471. DOI: 10.3390/foods12203726.

A Robust One-Step Recombineering System for Enterohemorrhagic .

Peng L, Dumevi R, Chitto M, Haarmann N, Berger P, Koudelka G Microorganisms. 2022; 10(9).

PMID: 36144292 PMC: 9504302. DOI: 10.3390/microorganisms10091689.

Enterohemorrhagic and a Fresh View on Shiga Toxin-Binding Glycosphingolipids of Primary Human Kidney and Colon Epithelial Cells and Their Toxin Susceptibility.

Detzner J, Pohlentz G, Muthing J Int J Mol Sci. 2022; 23(13).

PMID: 35805890 PMC: 9266556. DOI: 10.3390/ijms23136884.

References

Grif K, Dierich M, Karch H, Allerberger F . Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1999; 17(11):761-6. DOI: 10.1007/s100960050181. View

Muhldorfer I, Hacker J, Keusch G, Acheson D, Tschape H, Kane A . Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect Immun. 1996; 64(2):495-502. PMC: 173792. DOI: 10.1128/iai.64.2.495-502.1996. View

Collins J, Keeney K, Crepin V, Rathinam V, Fitzgerald K, Finlay B . Citrobacter rodentium: infection, inflammation and the microbiota. Nat Rev Microbiol. 2014; 12(9):612-23. DOI: 10.1038/nrmicro3315. View

Wong C, Jelacic S, Habeeb R, Watkins S, Tarr P . The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000; 342(26):1930-6. PMC: 3659814. DOI: 10.1056/NEJM200006293422601. View

Lee J, Stein B . Antimicrobials effective for inhibition of enterohaemorrhagic Escherichia coli strains O26, O111, and O157 and their effects on Shiga toxin releases. J Microbiol Biotechnol. 2009; 19(10):1238-43. View

Bielaszewska M, Mellmann A, Zhang W, Kock R, Fruth A, Bauwens A . Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis. 2011; 11(9):671-6. DOI: 10.1016/S1473-3099(11)70165-7. View

Karch H, Tarr P, Bielaszewska M . Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 2005; 295(6-7):405-18. DOI: 10.1016/j.ijmm.2005.06.009. View

Hiramatsu K, Murakami J, Kishi K, Hirata N, Yamasaki T, Kadota J . Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection. Int J Antimicrob Agents. 2003; 21(5):471-7. DOI: 10.1016/s0924-8579(03)00007-4. View

Karmali M, Steele B, Petric M, Lim C . Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983; 1(8325):619-20. DOI: 10.1016/s0140-6736(83)91795-6. View

10.

Friedrich A, Borell J, Bielaszewska M, Fruth A, Tschape H, Karch H . Shiga toxin 1c-producing Escherichia coli strains: phenotypic and genetic characterization and association with human disease. J Clin Microbiol. 2003; 41(6):2448-53. PMC: 156474. DOI: 10.1128/JCM.41.6.2448-2453.2003. View

11.

Zangari T, Melton-Celsa A, Panda A, Smith M, Tatarov I, De Tolla L . Enhanced virulence of the Escherichia coli O157:H7 spinach-associated outbreak strain in two animal models is associated with higher levels of Stx2 production after induction with ciprofloxacin. Infect Immun. 2014; 82(12):4968-77. PMC: 4249278. DOI: 10.1128/IAI.02361-14. View

12.

Yoh M, Frimpong E, Honda T . Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol. 1997; 19(1):57-64. DOI: 10.1111/j.1574-695X.1997.tb01072.x. View

13.

Friedrich A, Bielaszewska M, Zhang W, Pulz M, Kuczius T, Ammon A . Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis. 2002; 185(1):74-84. DOI: 10.1086/338115. View

14.

Zhang Y, Laing C, Zhang Z, Hallewell J, You C, Ziebell K . Lineage and host source are both correlated with levels of Shiga toxin 2 production by Escherichia coli O157:H7 strains. Appl Environ Microbiol. 2009; 76(2):474-82. PMC: 2805208. DOI: 10.1128/AEM.01288-09. View

15.

Yoshimura K, Fujii J, Taniguchi H, Yoshida S . Chemotherapy for enterohemorrhagic Escherichia coli O157:H infection in a mouse model. FEMS Immunol Med Microbiol. 1999; 26(2):101-8. DOI: 10.1111/j.1574-695X.1999.tb01376.x. View

16.

Kakoullis L, Papachristodoulou E, Chra P, Panos G . Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. J Infect. 2019; 79(2):75-94. DOI: 10.1016/j.jinf.2019.05.018. View

17.

Fadlallah S, Rahal E, Sabra A, Kissoyan K, Matar G . Effect of rifampicin and gentamicin on Shiga toxin 2 expression level and the SOS response in Escherichia coli O104:H4. Foodborne Pathog Dis. 2014; 12(1):47-55. DOI: 10.1089/fpd.2014.1824. View

18.

Newland J, Strockbine N, Miller S, OBrien A, Holmes R . Cloning of Shiga-like toxin structural genes from a toxin converting phage of Escherichia coli. Science. 1985; 230(4722):179-81. DOI: 10.1126/science.2994228. View

19.

Crepin V, Collins J, Habibzay M, Frankel G . Citrobacter rodentium mouse model of bacterial infection. Nat Protoc. 2016; 11(10):1851-76. DOI: 10.1038/nprot.2016.100. View

20.

Rahal E, Kazzi N, Kanbar A, Abdelnoor A, Matar G . Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice. Int J Antimicrob Agents. 2010; 37(2):135-9. DOI: 10.1016/j.ijantimicag.2010.10.009. View